Tag: SAVA

  • Crisis and Opportunity: Cassava Sciences Still a Strong Buy

    Crisis and Opportunity: Cassava Sciences Still a Strong Buy

    “With SAVA, once the pullback has exhausted itself, it’s a strong buy,” we noted on July 29. Since bottoming out around $65, the stock is back to $86.20 – and could refill its bearish gap around $140 with patience.  In fact, if the company can continue to progress with its Alzheimer’s treatment, this stock could…

  • Why Cassava Sciences Could be a Buy Again on Weakness

    Why Cassava Sciences Could be a Buy Again on Weakness

    On July 22, we mentioned Cassava Sciences was one of the hottest stocks on the market. In fact, since mentioning it, the stock ran from about $108 to $144.63. All thanks to a build-up of excitement ahead of its presentation at the 2021 Alzheimer’s Association International Conference.  Today, though, the stock is down about $11…

  • This is Why Cassava Sciences is Exploding Even Higher

    This is Why Cassava Sciences is Exploding Even Higher

    Cassava Sciences (SAVA) is one of the hottest stocks on the market. Since mentioning it yesterday, the stock has now run from $108 to $126.48. From here, it could see higher highs, as we near its presentation at the 2021 Alzheimer’s Association International Conference on July 26.  The presentations will include “Cassava Sciences’ investigational product…

  • This is Why Cassava Sciences (SAVA) Could Explode — Again

    This is Why Cassava Sciences (SAVA) Could Explode — Again

    Cassava Sciences (SAVA) is soaring again. After pulling back to strong support around $91, the stock is back to $108 thanks to new price targets, and progress on its lead drug candidate for Alzheimer’s. H.C. Wainwright raised its price target to $124 on SAVA.  Cantor Fitzgerald raised its target to $100.  Better, the company already…